ZO

Zomedica CorpNYSE-MKT ZOM Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.126

Micro

Exchange

XASE - Nyse MKT LLC

ZOM Stock Analysis

ZO

Uncovered

Zomedica Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

8/100

Low score

Market cap $B

0.126

Dividend yield

Shares outstanding

979.95 B

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is developing point-of-care diagnostic platform, which is based on miniaturized laser-based Raman spectroscopy technology and is designed to detect pathogens in companion animals. Its product portfolio includes diagnostics and therapeutic medical devices that emphasize patient health. The company offers TRUFORMA is a diagnostic biosensor platform and the first five assays for the detection of thyroid disorders in dogs and cats and adrenal disorders in dogs. The TRUFORMA platform uses bulk acoustic wave (BAW) technology to provide a non-optical and fluorescence free detection system for use at the point-of-care. The TRUFORMA also offers complete control over the testing process and allow veterinarians to make clinical decisions. PulseVet platform provides treatment for musculoskeletal issues in horses and small animals.

View Section: Eyestock Rating